T. Rowe Price Associates
BIIB icon

T. Rowe Price Associates’s Biogen BIIB Stock Holding History

T. Rowe Price Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123M Sell
672,427
-119,644
-15% -$22M 0.01% 575
2025
Q4 		$139M Sell
792,071
-173,386
-18% -$28.3M 0.02% 558
2025
Q3 		$135M Buy
965,457
+131,530
+16% +$17.8M 0.01% 551
2025
Q2 		$105M Sell
833,927
-317,265
-28% -$39.5M 0.01% 562
2025
Q1 		$158M Sell
1,151,192
-782,524
-40% -$112M 0.02% 474
2024
Q4 		$296M Buy
1,933,716
+21,170
+1% +$3.57M 0.03% 354
2024
Q3 		$371M Sell
1,912,546
-98,865
-5% -$20.7M 0.04% 324
2024
Q2 		$466M Buy
2,011,411
+421,782
+27% +$91.7M 0.06% 284
2024
Q1 		$343M Buy
1,589,629
+81,283
+5% +$19M 0.04% 335
2023
Q4 		$390M Buy
1,508,346
+344,816
+30% +$84.7M 0.05% 293
2023
Q3 		$299M Buy
1,163,530
+34,888
+3% +$9.33M 0.04% 320
2023
Q2 		$321M Sell
1,128,642
-959,714
-46% -$286M 0.04% 306
2023
Q1 		$581M Buy
2,088,356
+691,843
+50% +$191M 0.09% 226
2022
Q4 		$387M Sell
1,396,513
-138,002
-9% -$39M 0.06% 271
2022
Q3 		$410M Buy
1,534,515
+503,584
+49% +$107M 0.07% 252
2022
Q2 		$210M Sell
1,030,931
-45,038
-4% -$9.21M 0.03% 466
2022
Q1 		$227M Sell
1,075,969
-55,388
-5% -$12M 0.02% 493
2021
Q4 		$271M Sell
1,131,357
-652,779
-37% -$168M 0.02% 476
2021
Q3 		$505M Buy
1,784,136
+171,573
+11% +$56.2M 0.05% 343
2021
Q2 		$558M Sell
1,612,563
-164,608
-9% -$49.9M 0.05% 321
2021
Q1 		$497M Buy
1,777,171
+89,873
+5% +$24.2M 0.05% 338
2020
Q4 		$413M Buy
1,687,298
+316,017
+23% +$81.5M 0.04% 368
2020
Q3 		$389M Buy
1,371,281
+163,403
+14% +$45.6M 0.05% 341
2020
Q2 		$323M Sell
1,207,878
-3,076,679
-72% -$925M 0.04% 362
2020
Q1 		$1.36B Buy
4,284,557
+2,272,645
+113% +$690M 0.21% 101
2019
Q4 		$597M Buy
2,011,912
+907,258
+82% +$252M 0.08% 272
2019
Q3 		$257M Buy
1,104,654
+6,884
+0.6% +$1.6M 0.04% 398
2019
Q2 		$257M Buy
1,097,770
+45,881
+4% +$10.6M 0.04% 406
2019
Q1 		$249M Sell
1,051,889
-232,117
-18% -$73.1M 0.04% 412
2018
Q4 		$386M Sell
1,284,006
-499,136
-28% -$159M 0.07% 280
2018
Q3 		$630M Sell
1,783,142
-190,489
-10% -$65.6M 0.09% 226
2018
Q2 		$573M Sell
1,973,631
-2,048,468
-51% -$576M 0.09% 225
2018
Q1 		$1.1B Sell
4,022,099
-4,512,212
-53% -$1.4B 0.18% 130
2017
Q4 		$2.72B Sell
8,534,311
-2,147,067
-20% -$689M 0.44% 43
2017
Q3 		$3.34B Buy
10,681,378
+1,732,596
+19% +$513M 0.57% 30
2017
Q2 		$2.43B Buy
8,948,782
+830,591
+10% +$220M 0.44% 45
2017
Q1 		$2.22B Sell
8,118,191
-600,042
-7% -$170M 0.42% 49
2016
Q4 		$2.47B Buy
8,718,233
+1,108,205
+15% +$329M 0.49% 41
2016
Q3 		$2.38B Buy
7,610,028
+1,243,876
+20% +$368M 0.48% 43
2016
Q2 		$1.54B Sell
6,366,152
-1,753,757
-22% -$462M 0.33% 65
2016
Q1 		$2.11B Buy
8,119,909
+1,759,477
+28% +$465M 0.45% 42
2015
Q4 		$1.95B Buy
6,360,432
+333,346
+6% +$95.8M 0.41% 53
2015
Q3 		$1.76B Sell
6,027,086
-4,446,701
-42% -$1.47B 0.39% 55
2015
Q2 		$4.23B Sell
10,473,787
-317,775
-3% -$128M 0.87% 16
2015
Q1 		$4.56B Sell
10,791,562
-1,384,986
-11% -$546M 0.94% 13
2014
Q4 		$4.13B Sell
12,176,548
-614,504
-5% -$199M 0.88% 13
2014
Q3 		$4.23B Buy
12,791,052
+596,411
+5% +$197M 0.92% 11
2014
Q2 		$3.85B Buy
12,194,641
+16,492
+0.1% +$4.96M 0.83% 13
2014
Q1 		$3.72B Buy
12,178,149
+527,011
+5% +$167M 0.84% 9
2013
Q4 		$3.26B Buy
11,651,138
+823,942
+8% +$213M 0.75% 13
2013
Q3 		$2.61B Sell
10,827,196
-120,921
-1% -$27.1M 0.65% 19
2013
Q2 		$2.36B Buy
+10,948,117
New +$2.34B 0.63% 19

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates's BIIB Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Biogen (BIIB) stake by 15% in Q1 2026, selling an estimated $22M and leaving 672,427 shares worth $123M. The position accounts for 0.01% of the portfolio, ranked #575.

T. Rowe Price Associates first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.56B in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • T. Rowe Price Associates held 672,427 shares of Biogen worth $123M as of Q1 2026.
  • T. Rowe Price Associates sold 119,644 Biogen shares in Q1 2026, an estimated $22M.
  • Biogen made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #575 holding.
  • T. Rowe Price Associates first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Biogen position peaked at $4.56B in Q1 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.